Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Identify credit cards that provide excellent rewards without any fees. Get the most out of your spending.
28,655 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
NVIDIA hits fresh highs after U.S. regulators approve more H200 chip sales to China, lifting momentum across the AI c...
In a move that stirs controversy, a $1.7 billion fund is being created to compensate allies in a settlement tied to T...
A seven-name AI hardware rally is reshaping bets for 2026, with Parabolic 7 outpacing the Magnificent 7 and drawing n...
SpaceX is pursuing a landmark IPO with a $1.75 trillion target, a level that demands extraordinary growth. Experts ou...
NVIDIA CEO Jensen Huang positioned the latest AI stock pullback as a buying opportunity, a stance that reminds invest...
As AI workloads spur hyperscale data-center expansion, Vertiv’s order book signals a durable cycle that could lift th...
Civilians in the Black Sea peninsula face fuel shortages as russia-occupied crimea halts gas sales amid intensified U...
Institutional funds are piling into crypto stocks as a regulated way to gain exposure to digital assets. The question...
A coalition of twelve states filed a federal antitrust suit to block Paramount's $81 billion merger with Warner Bros....
When a CFO discloses a sizable stake sale during a volatile period, investors scramble for context. This article brea...
U.S. authorities have opened a preliminary inquiry into whether Binance facilitated Iran sanctions violations. The de...